ALLO News and Press, Allogene Therapeutics Inc. From 11/12/20

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in ...

Allogene Therapeutics, Inc. (ALLO) Q3 2020 Earnings Conference Call November 4, 2020 8:30 AM ET Company Participants Christine Cassiano – Chief Communications Officer David Chang – President and Chief Executive Officer Rafael Amado – Executive Vice President-Research and ...

Gainers: Biogen (BIIB) +40%.Cassava Sciences (SAVA) +26%.Athira Pharma (ATHA) +25%.Digirad (DRAD) +22%.Super Micro Computer (SMCI) +21%.Caesarstone (CSTE) +19%.XPeng (XPEV) +19%.Prothena (PRTA) +18%.TravelCenters of America (TA) +18%.Supernus Pharmaceuticals (SUPN) +18%.Losers: Repr...

Gainers: Biogen (BIIB) +43%, Digirad (DRAD) +28%, Supernus Pharmaceuticals (SUPN) +21%, Jupiter Wellness (JUPW) +3%, Cassava Sciences (SAVA) +13%.Losers: Repro Med Systems (KRMD) -28%, Aptevo Therapeutics (APVO) -13%, Allogene Therapeutics (AL...

Allogene Therapeutics ([[ALLO]] -17.1%) Q3 results:Cash, cash equivalents and investments of $1B.Research and development expenses of $51.4M (+28.5% Y/Y), which includes $8.8M of non-cash stock-based compensation expense.Pipeline Highlights: Initiate a three-pronged anti-BCMA strate...

ALLO-715, an Allogeneic BCMA CAR T Therapy Dosed with an ALLO-647 Based Lymphodepletion Regimen, Reported No Neurotoxicity or GvHD Across Three Cell Doses (40M, 120M, and 320M CAR+ cells) and Lower Dose (39mg) ALLO-647 Dose Dependent Activity Was Observed with 320M Cell Dose of ALLO...

Allogene Therapeutics (ALLO): Q3 GAAP EPS of -$0.52 beats by $0.03.Cash, cash equivalents and investments of $1B.Press Release For further details see: Allogene Therapeutics EPS beats by $0.03

Enrollment Ongoing in Phase 1 Trials of ALLO-501 (ALPHA), ALLO-501A (ALPHA2) and ALLO-715 (UNIVERSAL) Initial Phase 1 Results from the UNIVERSAL Trial in Relapsed/Refractory Multiple Myeloma to be Presented at a Medical Meeting in Q4 2020 In 1H 2021, Initial ALLO-501A Data and Upd...

Conference Call and Webcast Scheduled for 5:30 AM PT/8:30 AM ET SOUTH SAN FRANCISCO, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) ther...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...